In vivo BCMA CAR-T phase 1: 15 months of follow-up, one ongoing sCR
Green CAR-T cells attacking a red myeloma cell at right
New biomedical science, read from the primary paper: organoids, disease models, AI drug design, immunology, antibodies, nucleic-acid medicines and precision oncology. Plus China biopharma deals and partnering events, each linked to its source.
Green CAR-T cells attacking a red myeloma cell at right
A bispecific crossing airway epithelial cells and released at the airway surface
Green peptide-MHC complexes binding synthetic TCRs, with one non-reproducing case marked in red
Green immune cells attacking red tumour cells
Astrocytes in a brain organoid cross-section, with reactive cells in red
The green area in a brain cross-section is the transplanted human cortical organoid
A normal haematopoietic stem cell at left and a pyroptotic, ruptured cell at right
Alveoli and droplets at left, with the siRNA cleaving messenger RNA at right
Working on a China asset, a NewCo or a landscape report? See Services →
New science briefs, China out-licensing and NewCo deals, each with a link to the original source. Free; unsubscribe any time.